Latest:
Big Data Era Arrives in Clinical Practice Via CancerLinQ Project
This new approach—with a focus on personalized, data-driven decisions—is remaking healthcare, and more specifically, changing how oncologists treat cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
David E. Avigan, MD
Latest:
Dr. Avigan on BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma
David E. Avigan, MD, professor of medicine, Harvard Medical School, and active staff, Hematology-Oncology, Beth Israel Deaconess Medical Center, discusses BCMA-targeted CAR T-cell therapy in multiple myeloma.
David F. McDermott, MD
Latest:
Dr McDermott on the Eligibility Criteria of the LITESPARK-024 Trial in RCC
David F. McDermott, MD, discusses the ongoing, randomized, phase 1/2 LITESPARK-024 trial in patients with advanced renal cell carcinoma, highlighting the eligibility criteria for this clinical trial.
David Hyman, MD
Latest:
Dr. Hyman on MEDI3617 as Potential Treatment for Patients with Advanced Solid Tumors
David Hyman, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a phase I study of the selective angiopoietin-2 inhibitor MEDI3617 alone and in combination with carboplatin/paclitaxel, paclitaxel, or bevacizumab in patients with advanced solid tumors.
David I. Quinn, MBBS, PhD
Latest:
Dr. Quinn on Targetable Molecular Pathways in RCC
David I. Quinn, MBBS, PhD, associate professor of medicine, section head, Genitourinary Oncology, Division of Cancer Medicine and Blood Diseases, USC Keck School of Medicine, discusses targetable molecular pathways in renal cell carcinoma.
David I. Quinn, MD, MBBS, PhD, FRACP, FACP
Latest:
Dr. Quinn on Novel Hormonal Therapies in Prostate Cancer
David I. Quinn, MD, MBBS, PhD, FRACP, FACP, associate professor of medicine, section head, Genitourinary Oncology, Division of Cancer Medicine and Blood Diseases, Department of Medicine, Keck School of Medicine, discusses the rise of novel hormonal therapies in prostate cancer.
David I. Quinn, MD, PhD
Latest:
Dr. Quinn on Current State of Biomarkers in RCC
David I. Quinn, MD, PhD, associate professor of medicine, section head, Genitourinary Oncology, Division of Cancer Medicine and Blood Diseases, Keck School of Medicine, discusses the current state of biomarkers in renal cell carcinoma.